FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964751282> ?p ?o ?g. }

• W2964751282 endingPage "145" @default.
• W2964751282 startingPage "135" @default.
• W2964751282 abstract "Objective: To determine the efficacy of pembrolizumab relative to other treatments used in stage III melanoma by conducting a systematic literature review (SLR) and network meta-analysis (NMA). Methods: A SLR was conducted to identify randomized clinical trials (RCTs) evaluating approved adjuvant treatments including interferon-containing regimens, BRAF-inhibitors, and PD-L1 inhibitors in stage III melanoma patients. Relative treatment effects for recurrence-free survival (RFS) were synthesized with Bayesian NMA models that allowed for hazard ratios (HRs) to vary over time. Results: Included studies formed a connected network of evidence composed of eight trials. In high-risk stage III patients, the HR for pembrolizumab vs observation decreased significantly over time with the superiority of pembrolizumab over observation becoming statistically meaningful before 3 months. By 9 months, the HR for pembrolizumab vs observation was statistically significantly lower than the HR for most other treatments vs observation, with the exception of ipilimumab and biochemotherapy due to overlapping 95% credible intervals. In BRAF + patients, pembrolizumab was statistically significantly better than observation after 3 months. The HR for both BRAF-inhibitors vs observation increased significantly over time and pembrolizumab was statistically superior to both BRAF-inhibitors after 15 months. Conclusions: Pembrolizumab results in statistically significantly improved RFS compared to all competing regimens after 9 months, except ipilimumab and biochemotherapy, for the adjuvant treatment of stage III melanoma. However, point estimate HRs vs observation for pembrolizumab are much lower than those for ipilimumab. In BRAF + patients, the advantage of pembrolizumab versus competing interventions increases over time with respect to RFS." @default.
• W2964751282 created "2019-08-13" @default.
• W2964751282 creator A5014482100 @default.
• W2964751282 creator A5037620517 @default.
• W2964751282 creator A5050381719 @default.
• W2964751282 creator A5064925554 @default.
• W2964751282 creator A5070868126 @default.
• W2964751282 creator A5091485339 @default.
• W2964751282 date "2019-01-01" @default.
• W2964751282 modified "2023-09-23" @default.
• W2964751282 title "An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma" @default.
• W2964751282 cites W1552882882 @default.
• W2964751282 cites W156085488 @default.
• W2964751282 cites W1828940258 @default.
• W2964751282 cites W1966561347 @default.
• W2964751282 cites W1967385770 @default.
• W2964751282 cites W2033044997 @default.
• W2964751282 cites W2042044430 @default.
• W2964751282 cites W2059573268 @default.
• W2964751282 cites W2070825440 @default.
• W2964751282 cites W2072673200 @default.
• W2964751282 cites W2076668534 @default.
• W2964751282 cites W2096870516 @default.
• W2964751282 cites W2097691839 @default.
• W2964751282 cites W2098923148 @default.
• W2964751282 cites W2099289479 @default.
• W2964751282 cites W2108495932 @default.
• W2964751282 cites W2109534056 @default.
• W2964751282 cites W2113144077 @default.
• W2964751282 cites W2114160093 @default.
• W2964751282 cites W2123628301 @default.
• W2964751282 cites W2124847703 @default.
• W2964751282 cites W2126634195 @default.
• W2964751282 cites W2131772284 @default.
• W2964751282 cites W2161671887 @default.
• W2964751282 cites W2164130643 @default.
• W2964751282 cites W2269457085 @default.
• W2964751282 cites W2324398668 @default.
• W2964751282 cites W2529373149 @default.
• W2964751282 cites W2560322684 @default.
• W2964751282 cites W2583263803 @default.
• W2964751282 cites W2587970821 @default.
• W2964751282 cites W2588681363 @default.
• W2964751282 cites W2600953752 @default.
• W2964751282 cites W2601468666 @default.
• W2964751282 cites W2624147378 @default.
• W2964751282 cites W2725988420 @default.
• W2964751282 cites W2752210999 @default.
• W2964751282 cites W2752227448 @default.
• W2964751282 cites W2761381159 @default.
• W2964751282 cites W2788938550 @default.
• W2964751282 cites W2793701502 @default.
• W2964751282 cites W2797309423 @default.
• W2964751282 cites W2806413494 @default.
• W2964751282 cites W2896253897 @default.
• W2964751282 cites W2922063178 @default.
• W2964751282 doi "https://doi.org/10.1080/21556660.2019.1649266" @default.
• W2964751282 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6713115" @default.
• W2964751282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31489255" @default.
• W2964751282 hasPublicationYear "2019" @default.
• W2964751282 type Work @default.
• W2964751282 sameAs 2964751282 @default.
• W2964751282 citedByCount "7" @default.
• W2964751282 countsByYear W29647512822020 @default.
• W2964751282 countsByYear W29647512822021 @default.
• W2964751282 countsByYear W29647512822022 @default.
• W2964751282 countsByYear W29647512822023 @default.
• W2964751282 crossrefType "journal-article" @default.
• W2964751282 hasAuthorship W2964751282A5014482100 @default.
• W2964751282 hasAuthorship W2964751282A5037620517 @default.
• W2964751282 hasAuthorship W2964751282A5050381719 @default.
• W2964751282 hasAuthorship W2964751282A5064925554 @default.
• W2964751282 hasAuthorship W2964751282A5070868126 @default.
• W2964751282 hasAuthorship W2964751282A5091485339 @default.
• W2964751282 hasBestOaLocation W29647512821 @default.
• W2964751282 hasConcept C121608353 @default.
• W2964751282 hasConcept C126322002 @default.
• W2964751282 hasConcept C143998085 @default.
• W2964751282 hasConcept C146357865 @default.
• W2964751282 hasConcept C151730666 @default.
• W2964751282 hasConcept C168563851 @default.
• W2964751282 hasConcept C207103383 @default.
• W2964751282 hasConcept C2777658100 @default.
• W2964751282 hasConcept C2777701055 @default.
• W2964751282 hasConcept C2777863537 @default.
• W2964751282 hasConcept C2780057760 @default.
• W2964751282 hasConcept C2781433595 @default.
• W2964751282 hasConcept C44249647 @default.
• W2964751282 hasConcept C502942594 @default.
• W2964751282 hasConcept C535046627 @default.
• W2964751282 hasConcept C71924100 @default.
• W2964751282 hasConcept C86803240 @default.
• W2964751282 hasConceptScore W2964751282C121608353 @default.
• W2964751282 hasConceptScore W2964751282C126322002 @default.
• W2964751282 hasConceptScore W2964751282C143998085 @default.
• W2964751282 hasConceptScore W2964751282C146357865 @default.
• W2964751282 hasConceptScore W2964751282C151730666 @default.
• W2964751282 hasConceptScore W2964751282C168563851 @default.

• next